Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GASPS Study
2024-520127-89-00Phase 4Authorised
- Sponsor
- Region Örebro län
- Start
- Mar 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of propofol, remifentanil, bupivacaine, sufentanil and fentanyl in knee osteoarthritis (OA), hip osteoarthritis and autoimmune arthritis (2 arms), sponsored by Region Örebro län. Primary endpoint: Successful same-day discharge. Planned start Mar 2026; status: authorised.
02
Drugs
propofolremifentanilbupivacainesufentanilfentanyl
03
Conditions
knee osteoarthritis (OA)hip osteoarthritisautoimmune arthritis
Beyond the preview
Go deeper on 2024-520127-89-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520127-89-00.